FindTrial
Sign In

Randomized Controlled Clinical Study on the Effect of Jin Xinkang Granules in the Intervention of Pump Failure After Percutaneous Coronary Intervention in Patients with Acute ST-Segment Elevation Myocardial Infarction.

Randomized Controlled Clinical Study on the Effect ooronary Interventif Jin Xinkang Granules in the Intervention of Pump Failure After Percutaneous Con in Patients with Acute ST-Segment Elevation Myocardial Infarction.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000158
Enrollment
Unknown
Registered
2025-01-23
Start date
2025-01-24
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pump Failure After Percutaneous Coronary Intervention in Patients with Acute ST-Segment Elevation Myocardial Infarction

Interventions

Jin Xinkang Granules treatment group:Conventional Western medicine treatment + Jin Xinkang Granules treatment
Placebo group:Conventional Western medicine treatment + Jin Xinkang placebo treatment
Jin Xinkang Traditional Chinese Medicine Decoction Group:Conventional Western medicine treatment + Jin Xinkang Chinese medicine decoction treatment

Sponsors

The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Meets the diagnostic criteria for acute ST-segment elevation myocardial infarction (STEMI); 2. Successfully underwent PCI reperfusion therapy; 3. Echocardiography: Left ventricular ejection fraction (LVEF) = 50%; 4. Killip classification: Grade II–III; 5. Age between 18 and 80 years.

Exclusion criteria

Exclusion criteria: 1. Have used other experimental drugs other Chinese medicines or proprietary Chinese medicines in the past month; 2. Known to have an adverse reaction to the study drug; 3. Known to be allergic to the study drug; 4. Severe liver dysfunction (ALT > 100 U/L or AST > 100 U/L); 5. Severe renal dysfunction (glomerular filtration rate < 30 ml/min); 6. Hematological diseases or malignant tumors; 7. Pregnancy or breastfeeding; 8. Psychiatric disorders; 9. Uncontrolled hypertension or diabetes.

Design outcomes

Primary

MeasureTime frame
Left ventricular ejection fraction (LVEF Simpson's method);—

Secondary

MeasureTime frame
liver and kidney function;Adverse cardiovascular events;Chinese Medicine Symptoms and Signs;routine blood test;Echocardiographic indices (LVEDD LVESD IVS LVPW FS E/e' E/A etc.);NT-proBNP;coagulation function;Macro- and micro-indicators associated with the four-dimensional triangle of heart failure;Twelve-lead electrocardiogram (ECG);Routine stool examination;Minnesota Heart Failure Quality of Life Scale;Routine urine tests;6-minute walk test;electrolyte examination;—

Countries

China

Contacts

Public ContactZhao Xinjun

The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine

zxjhwxm@sina.com15625078269

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026